{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:03:20Z","timestamp":1790597000993,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clinthera.2022.03.013","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T20:09:23Z","timestamp":1657138163000},"page":"1012-1025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review"],"prefix":"10.1016","volume":"44","author":[{"given":"Raabya","family":"Pasha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-6988","authenticated-orcid":false,"given":"Shazli","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ferdousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alise","family":"Kalteniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8331","authenticated-orcid":false,"given":"Bilal","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-8903","authenticated-orcid":false,"given":"Rayaz A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.03.013_bib0001","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.amjmed.2019.01.042","article-title":"Prescribing statins to reduce cardiovascular disease: 10 common misconceptions","volume":"132","author":"Schade","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0002","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0003","series-title":"Hyperlidaemia: Diagnosis & Management","author":"Durrington","year":"2007"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0004","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1523\/JNEUROSCI.22-05-01679.2002","article-title":"Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells","volume":"22","author":"Runz","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0005","first-page":"s108","article-title":"Statins an oft-prescribed drug is implicated in peripheral neuropathy: the time to know more","volume":"69","author":"Al-kuraishy","year":"2019","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.600950","article-title":"Oxidized LDL causes endothelial apoptosis by inhibiting mitochondrial fusion and mitochondria autophagy","volume":"8","author":"Zheng","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1529-8027.2009.00237.x","article-title":"Hyperlipidemia: a new therapeutic target for diabetic neuropathy","volume":"14","author":"Vincent","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0008","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s001250100615","article-title":"The metabolic syndrome influences the risk of chronic complications in patients with type 2 diabetes","volume":"44","author":"Isomaa","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1900\/RDS.2015.12.13","article-title":"Vascular impairment of epineurial arterioles of the sciatic nerve: implications for diabetic peripheral neuropathy","volume":"12","author":"Yorek","year":"2015","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00505180","article-title":"Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy","volume":"32","author":"Malik","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOL.0000000000000770","article-title":"Lipids and peripheral neuropathy","volume":"32","author":"Iqbal","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0012","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1592\/phco.24.13.1194.38084","article-title":"Statin-associated peripheral neuropathy: review of the literature","volume":"24","author":"Chong","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0013","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0014","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity: mechanistic insights and clinical implications","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2362.1994.tb00984.x","article-title":"Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors","volume":"24","author":"Sehayek","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.06.023","article-title":"Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance","volume":"306","author":"Soran","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0017","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2018.08.040","article-title":"Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk","volume":"278","author":"Soran","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0018","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/2047487316667785","article-title":"Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat","volume":"24","author":"Soran","year":"2017","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MOL.0000000000000433","article-title":"Evidence for more intensive cholesterol lowering","volume":"28","author":"Soran","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0020","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","author":"Endo","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0021","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,00 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0022","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0023","doi-asserted-by":"crossref","first-page":"a993","DOI":"10.1136\/bmj.a993","article-title":"Hypercholesterolaemia and its management","volume":"337","author":"Bhatnagar","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacl.2017.10.011","article-title":"A comparison of the effects of low- and high- dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial","volume":"12","author":"Soran","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0026","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0027","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.3390\/ijms151120607","article-title":"Molecular mechanisms underlying the effects of statins in the central nervous system","volume":"15","author":"McFarland","year":"2014","journal-title":"Int J Molecul Sci"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0028","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence\u2014focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4137\/LPI.S37450","article-title":"Current and emerging uses of statins in clinical therapeutics: a review","volume":"9","author":"Davies","year":"2016","journal-title":"Lipid Insights"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0031","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0032","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of stating therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nature Rev Cardiol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0033","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survery of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","article-title":"Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey","volume":"245","author":"Hovingh","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0036","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jacl.2008.01.002","article-title":"Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising","volume":"2","author":"Kon","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0037","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0038","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0039","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","article-title":"Are statins diabetogenic?","volume":"26","author":"Sampson","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0040","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Taskforce: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0041","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0042","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: pros and cons","volume":"150","author":"Pinal-Fernandez","year":"2018","journal-title":"Medicina Clinica"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0043","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MOL.0000000000000526","article-title":"Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets","volume":"29","author":"Soran","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0044","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2337\/dc14-2733","article-title":"Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes","volume":"38","author":"Azmi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0045","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2337\/diabetes.52.12.2867","article-title":"Microvascular complications of impaired glucose tolerance","volume":"52","author":"Singleton","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0046","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2337\/dc14-0279","article-title":"Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance","volume":"37","author":"Asghar","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0047","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/106002800303700220","article-title":"Association of HMG-CoA reductase inhibitors with neuropathy","volume":"37","author":"Backes","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0048","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/jnnp.58.5.625","article-title":"Peripheral neuropathy associated with simvastatin","volume":"58","author":"Phan","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0049","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s002280000248","article-title":"Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?","volume":"56","author":"Gaist","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0050","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/bcp.13298","article-title":"Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013","volume":"83","author":"Svendsen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0051","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bcpt.13320","article-title":"Statin use and peripheral nerve function\u2014a prospective follow-up study","volume":"126","author":"Svendsen","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0052","doi-asserted-by":"crossref","first-page":"e2136","DOI":"10.1212\/WNL.0000000000007148","article-title":"Statins do not increase risk of polyneuropathy","volume":"92","author":"Warendorf","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0053","first-page":"401","article-title":"Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study","volume":"7","author":"Hern\u00e1ndez-Ojeda","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0054","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00125-007-0919-2","article-title":"Lipid-Lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study","volume":"51","author":"Davis","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40122-020-00153-9","article-title":"Statins and neuropathic pain: a narrative review","volume":"9","author":"Pergolizzi","year":"2020","journal-title":"Pain Therapy"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0056","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27086","article-title":"Metabolic syndrome and peripheral neuropathy","volume":"63","author":"Kazamel","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0057","article-title":"Small fiber neuropathy associated with hyperlidemia: utility of cutaneous silent periods and autonomic tests","author":"Morkavuk","year":"2014","journal-title":"Int Sch Res Notices"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0058","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.2337\/db06-1176","article-title":"High-fat diet induced neuropathy of pre-diabetes and obesity: effects of 'healthy' diet and aldose reductase inhibition","volume":"56","author":"Obrosova","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0059","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2011.137","article-title":"Diabetic neuropathy: cellular mechanisms as therapeutic targets","volume":"7","author":"Vincent","year":"2011","journal-title":"Nature Rev Neurol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0061","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2337\/dc19-1583","article-title":"The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D Exchange","volume":"43","author":"Mizokami-Stout","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0062","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jdiacomp.2013.04.003","article-title":"Obesity and hyperlipidemia are risk factors for early diabetic neuropathy","volume":"27","author":"Smith","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0063","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.2337\/dc18-1411","article-title":"Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0064","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/dme.12176","article-title":"Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes","volume":"30","author":"Jang","year":"2013","journal-title":"Diabetic Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0065","first-page":"26","article-title":"Neuropathy associated with hypertriglyceridemia in patients with metabolic syndrome","volume":"12","author":"Beyca","year":"2016","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0066","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc19-2277","article-title":"Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,248 patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort","volume":"43","author":"Christensen","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0067","doi-asserted-by":"crossref","first-page":"e3044","DOI":"10.1002\/dmrr.3044","article-title":"Explanations for less small fibre neuropathy in South Asian versus European subjects with type 2 diabetes in the UK","volume":"34","author":"Fadavi","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0068","first-page":"11","article-title":"The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity","author":"Azmi","year":"2021","journal-title":"Scientific Rep"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0069","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41598-020-79276-0","article-title":"A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy","volume":"11","author":"Cai","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0070","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jdiacomp.2018.09.016","article-title":"Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark","volume":"32","author":"Andersen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0071","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11695-020-05052-8","article-title":"Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study","volume":"31","author":"Adam","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0072","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41366-020-00727-9","article-title":"Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity","volume":"45","author":"Azmi","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0073","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1464-5491.2010.03110.x","article-title":"Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis","volume":"27","author":"Perkins","year":"2010","journal-title":"Diabetic Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0074","first-page":"775","article-title":"Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients","volume":"26","author":"Kassem","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.32007\/jfacmedbagdad.5011315","article-title":"The role of hyperlidemia on nerve conduction","volume":"50","author":"Al-Shareefi","year":"2008","journal-title":"J Fac Med Baghdad"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0076","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0077","first-page":"101","article-title":"Treatment with statins and peripheral neuropathy: results of 36-months a prospective clinical and neurophysiological follow-up","volume":"32","author":"Otruba","year":"2011","journal-title":"Neuroendocrinol Lett"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0078","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dsx.2020.04.005","article-title":"Statins-related peripheral neuropathy among diabetic patients","volume":"14","author":"Hammad","year":"2020","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0079","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jech.2003.013409","article-title":"lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases","volume":"58","author":"Corrao","year":"2004","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1753-0407.12013","article-title":"Association of statin use with peripheral neuropathy in the US population 40 years of age or older","volume":"5","author":"Tierney","year":"2013","journal-title":"J Diabetes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0081","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(14)70173-1","article-title":"Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study","volume":"2","author":"Nielsen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0082","first-page":"12","article-title":"Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis","author":"Macedo","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0083","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc20-1004","article-title":"Statin therapy and risk of polyneuropathy in type 2 diabetes: a Danish cohort study","volume":"43","author":"Kristensen","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0084","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40263-013-0135-1","article-title":"Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management","volume":"28","author":"Tuccori","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0306-4530(02)00014-8","article-title":"Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial","volume":"28","author":"Hyypp\u00e4","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0086","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1001\/archinte.160.20.3144","article-title":"Long-term association of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin","volume":"160","author":"Stewart","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0087","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.19082\/6527","article-title":"Lipid-lowering drugs (statins) and peripheral neuropathy","volume":"10","author":"Emad","year":"2018","journal-title":"Electronic Physician"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0088","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0089","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.expneurol.2010.04.006","article-title":"Statins: multiple neuroprotective mechanisms in neurodegenerative diseases","volume":"230","author":"Wang","year":"2011","journal-title":"Experimental Neurol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.brainresrev.2007.10.010","article-title":"Neuroprotection by pravastatin in acute ischemic stroke in rats","volume":"58","author":"Berger","year":"2008","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0091","doi-asserted-by":"crossref","first-page":"e12108","DOI":"10.1002\/trc2.12108","article-title":"Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases","volume":"6","author":"Torrandell-Haro","year":"2020","journal-title":"Trans Res Clin Intervent"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0092","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/pds.3381","article-title":"Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding","volume":"22","author":"Wong","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0093","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/j.1552-4604.1996.tb04242.x","article-title":"Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects","volume":"36","author":"Posvar","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-018-0110-3","article-title":"The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms","volume":"7","author":"Schultz","year":"2018","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","article-title":"Statin-associated memory loss: analysis of 60 case reports and review of the literature","volume":"23","author":"Wagstaff","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0096","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","article-title":"Statins: then and now","volume":"15","author":"Toth","year":"2019","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0097","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6943851","article-title":"Lipids: a suitable therapeutic target in diabetic neuropathy?","volume":"2017","author":"Perez-Matos","year":"2017","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0099","first-page":"1","article-title":"Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db\/db mice","volume":"9","author":"Cho","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc20-1482","article-title":"Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: a corneal confocal microscopy study","volume":"44","author":"Ferdousi","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0101","doi-asserted-by":"crossref","DOI":"10.2337\/db08-1771","article-title":"Elevated triglycerides correlate with progression of diabetic neuropathy","volume":"58","author":"Wiggin","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0102","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jnnp.66.3.410a","article-title":"Jonville-Bera A. Severe toxic neuropathy due to fibrates","volume":"66","author":"Corcia","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0103","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0105","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0106","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0107","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0108","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11739-017-1708-7","article-title":"PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Squizzato","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0109","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/pedi.12490","article-title":"Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women","volume":"18","author":"Levenson","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0110","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.2337\/dc16-2563","article-title":"PCSK9 is increased in youth with type 1 diabetes","volume":"40","author":"Levenson","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0111","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.numecd.2016.12.010","article-title":"Calorically restricted diets decrease PCSK9 in overweight adolescents","volume":"27","author":"Levenson","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.exer.2013.06.013","article-title":"Relaxation of porcine retinal arterioles exposed to hypercholesterolemia in vivo is modified by hepatic LDL-receptor deficiency and diabetes mellitus","volume":"115","author":"Bek","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0113","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jnc.13397","article-title":"Nerve growth factor (NGF) and pro-NGF increase low-density lipoprotein (LDL) receptors in neuronal cells partly by different mechanisms: role of LDL in neurite outgrowth","volume":"136","author":"Do","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0114","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.yexcr.2016.01.001","article-title":"Stress-induced upregulation of VLDL receptor alters Wnt-signaling in neurons","volume":"340","author":"Kysenius","year":"2016","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3892\/mmr.2016.6055","article-title":"Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-\/-) mice may be associated with increased PCSK9 expression","volume":"15","author":"Zhao","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0116","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0117","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0118","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"Giugliano","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0119","unstructured":"FDA advises of adverse effects from new cholesterol drugs [Available from: http:\/\/www.wsj.com\/articles\/SB10001424052702304732804579425612487904436] 2022."},{"key":"10.1016\/j.clinthera.2022.03.013_bib0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acn3.746","article-title":"Association of corneal nerve fiber measures with cognitive function in dementia","volume":"6","author":"Ponirakis","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0121","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3233\/JAD-200678","article-title":"Corneal nerve and brain imaging in mild cognitive impairment and dementia","volume":"77","author":"Al-Janahi","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinthera.2022.03.013_bib0122","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.atherosclerosis.2020.10.673","article-title":"PCSK9 monoclonal antibody treatment promotes small fibre regeneration in heterozygous familial hypercholesterolemia","volume":"315","author":"Soran","year":"2020","journal-title":"Atherosclerosis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:00Z","timestamp":1758963420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822001382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0149291822001382"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.03.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}